Merck Commits $510M to AI Drug Design Partnership with Protillion

Strategic News Watch — June 16, 2026

Merck pledged up to $510 million in biobucks to Protillion’s AI drug-design platform — one of the quarter’s larger computational partnerships — as the FDA and MHRA opened a new collaboration on devices and AI oversight and Germany retreated from its variable pharma rebate plan after industry pushback.

Today’s top developments:

Merck & Co. signed a collaboration and license agreement worth up to $510 million in biobucks with AI drug design specialist Protillion (Fierce Biotech)
The FDA and UK’s MHRA launched a new collaborative initiative to improve oversight of medical devices, AI in healthcare, and innovative medicines (Pharmaceutical Technology)
Germany is reportedly dropping the variable-rebate component of its draft GKV-BStabG law, retaining the current 7% fixed markdown on patent-protected medicines (pharmaphorum)
Edgewise Therapeutics released phase 2 cardiomyopathy data supporting pivotal development, positioning it to challenge Bristol Myers Squibb and Cytokinetics (Fierce Biotech)
Eli Lilly struck a GLP-2 partnership with South Korea’s Hanmi Pharmaceutical to extend its incretin franchise into gastrointestinal indications (PharmaVoice)
Corvus Pharmaceuticals CEO Richard Miller called the company’s lead ITK inhibitor potentially “Rituxan all over again,” projecting blockbuster potential across oncology and autoimmune indications (PharmaVoice)
IRA reforms corrected Medicare Part D distortions that favored high-list, high-rebate branded multiple sclerosis drugs, but patients now face new coverage tradeoffs (Drug Channels)

What to Watch

German Pharma Pricing Reform — The reported retreat on variable rebates removes one headwind for the German market, but the broader GKV-BStabG bill — reimbursement price freezes through 2030, binding AMNOG price/volume discounts, and vaccine rebates — still threatens pharma capital allocation in Europe’s largest pharma economy and sets precedent for adjacent EU markets.
GLP Franchise Expansion — Lilly’s GLP-2 move into GI disease suggests the company is building a multi-pronged defense of its incretin dominance; expect competitors to respond with their own adjacency plays or targeted acquisitions.
Cardiomyopathy Market Crowding — With Edgewise, BMS, and Cytokinetics all advancing programs, the rare cardiomyopathy space is becoming competitive enough to potentially trigger consolidation or partnership activity before phase 3 readouts.
FDA-MHRA Harmonization Impact — The new regulatory collaboration could materially shorten approval timelines for AI-enabled diagnostics and digital therapeutics seeking simultaneous US-UK market entry, creating first-mover advantages.

This brief highlights the edition’s top stories. Read the latest edition → for all stories and analysis.

Related Stories

Mahzi Lets Rare-Disease Families Invest in Its Gene Therapy

FDA Posts 14 New Rejection Letters Just Days After Confirming a Pause

Roche Scraps Two Ionis-Partnered Huntington’s Studies After Tominersen Failure